Fax: 561-516-6626 | Email: Info@infuseone.com | Phone 561-337-4055

Qutenza (capsaicin) Order Form

INFUSE ONE

Patient Name: DOB: ☐ Male ☐ Female

Diagnosis (please provide ICD10 code)

Other: ☐ NKDA Allergies:

☐ New Start Therapy ☐ Continuation of Therapy Date of last dose (if applicable):

Ordering Provider:

Provider NPI: Phone: Fax:

Practice Address: City: State: Zip Code:

Practice Contact: Email (for updates):

QUTENZA ORDERS

DOSING:

- ☐ 1 Topical System (1 patch - 280cm^2 billing units)
- ☐ 2 Topical Systems (2 patches- 560cm^2 billing units)
- ☐ 3 Topical Systems (3 patches- 840cm^2 billing units)
- ☐ 4 Topical Systems (4 patches-1120cm^2 billing units)

LOCATION OF PATCH AND APPLICATION TIME:

- ☐ Left Foot (Dx: Diabetic Peripheral Neuropathy: 30 minute application)
- ☐ Right Foot (Dx: Diabetic Peripheral Neuropathy: 30 minute application)
- ☐ Right Side (Dx Post Herpetic Neuralgia : 60 minute application)
- ☐ Left Side (Dx Post Herpetic Neuralgia : 60 minute application)

REQUIRED TESTING/LABS:

- ☑ Clinical/Progress Notes, Labs, Tests supporting primary diagnosis (please attach)

FREQUENCY:

- ☑ Every 3 months

Other: _____

REFILLS:

- ☐ _____
- ☐ One year from date signed

Infuse One Standing Orders:

- ☑ Provide treatment under Infuse One's Clinical Guidelines, Medication Safety Protocol, Emergency Guidelines, and Action Plan for Infusion Reactions.

_____

Provider Name

_____ _____

Provider Signature Date

Capsaicin can cause severe irritation of eyes, mucous membranes, respiratory tract, and skin to the healthcare professional, patients, and others.
Patients may experience substantial procedural pain and burning upon application of Qutenza and following removal of Qutenza. Prepare to treat acute pain during and following the application procedure with local cooling (such as an ice pack) and/or appropriate analgesic medication.
ransient increases in blood pressure may occur with Qutenza treatment. Monitor blood pressure during and following the treatment procedure.
Reductions in sensory function, which were generally minor and temporary, have been reported following administration of Qutenza. All patients with sensory deficits should be assessed for signs of sensory deterioration or loss prior to each application of Qutenza. If sensory loss occurs, treatment should be reconsidered.